ARTICLE | Company News
Viamet cancer, infectious news
October 27, 2014 7:00 AM UTC
Viamet said it will spin out its prostate cancer program to existing investors in a newco called Innocrin Pharmaceuticals, led by former Viamet CSO William Moore. Innocrin will be investigating VT-46...